An increasingly large body of work suggests that many illicit psychoactive drugs could be useful as treatments for certain mental health problems. Studies have found, for instance, that the psychedelics psilocybin (from magic mushrooms) and LSD can reduce symptoms of anxiety and depression, while MDMA may be useful in treating PTSD.
It’s a different story for a practice known as “microdosing”, however. This involves taking a small quantity of a psychedelic substance — normally too little to produce any perceptible effects — repeatedly over a period of time (every few days for several weeks, say). And as we reported in 2019, although results from some surveys or poorly-controlled trials suggest that microdosing can improve people’s mood or certain aspects of cognition, more rigorous placebo-controlled trials have failed to find any such effects.
A new study in Scientific Reports could explain why. The team, led by Laura Kartner from Imperial College London, finds that people who plan on microdosing do go on to experience a boost to wellbeing and a reduction in anxiety and depression. But the level of improvement depends on how much they expect to improve in the first place, suggesting that any effects on wellbeing may be the result of a strong placebo response.Continue reading “Supposed Benefits Of Psychedelic Microdosing To Mental Health May Actually Reflect Strong Placebo Response”